Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, and CNS Lymphoma Diagnosis and Treatment.
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<scp>GemOx</scp>: A Multicenter Cohort Study
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium.
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool.
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda.
Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy.
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis.
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Transformation of marginal zone lymphoma to Hodgkin lymphoma.
Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma.
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
Outcomes of patients with <scp>limited‐stage</scp> plasmablastic lymphoma: A <scp>multi‐institutional</scp> retrospective study
Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy
Comparing Clinical Characteristics and Outcomes of <i>MYC</i> and <i>BCL6</i> Double Hit Lymphoma (DHL- <i>BCL6</i>) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.